Clinical Trials Browser

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Phase 2 Completed

15 enrolled 17 charts

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

NCT06421675 2025-11-14

EMBRACE

Phase 2 Recruiting

40 enrolled

Plasma cell

Cytokine Release Syndrome, Multiple Myeloma, Recurrence

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Phase 1/2 Active not recruiting

17 enrolled

LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04975555 2025-09-22

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Phase 2 Active not recruiting

30 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Phase 2 Recruiting

20 enrolled

Plasma cell

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT06703216 2025-06-15

PACER

Phase 1/2 Not yet recruiting

24 enrolled

Lymphoid

Cytokine Release Syndrome, Burkitt Lymphoma

NCT06447376 2025-05-11

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Phase 1 Recruiting

20 enrolled

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin

NCT06352866 2025-03-03

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Phase 2 Withdrawn

Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT04466098 2025-01-29

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

Phase 2 Completed

8 enrolled 21 charts

Lymphoid

Cytokine Release Syndrome, COVID-19, Lymphoma, Follicular, Respiratory Distress Syndrome

NCT05510596 2024-08-09

MR-ICANS

Phase NA Completed

25 enrolled

Lymphoid

Cytokine Release Syndrome, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT04358406 2023-11-28

Rhu-pGSN for Severe Covid-19 Pneumonia

Phase 2 Completed

64 enrolled 17 charts

Lymphoid

Cytokine Release Syndrome, COVID-19, Lymphoma, Follicular, Pneumonia

NCT03557749 2023-08-21

Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

Terminated

210 enrolled

Cytokine Release Syndrome, Bronchiolitis Obliterans Syndrome, Neoplasms

NCT05414162 2022-06-15

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Unknown

60 enrolled

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Follicular, Multiple Myeloma, Myocarditis

NCT04082910 2022-04-13

Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

Phase 1/2 Unknown

30 enrolled

Other hematologic neoplasm

Cytokine Release Syndrome, Hematologic Neoplasms

NCT04394182 2022-03-29

ULTRA-COVID

Phase NA Suspended

15 enrolled

Cytokine Release Syndrome, Pneumonia, Viral, Respiratory Distress Syndrome

NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Phase 1 Completed

17 enrolled 17 charts

CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

NCT02000817 2019-06-24

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

Phase 1/2 Completed

30 enrolled 21 charts

Cytokine Release Syndrome, Diabetes Mellitus, Diabetes Mellitus, Type 1, Epstein-Barr Virus Infections

NCT01302223 2012-12-06

Keratinocyte Growth Factor and Cytokines in Burns.

Completed

8 enrolled

Growth Factors, Combined Defect of, Cytokine Release Syndrome, Burns, Inflammation

Clinical Trials

Early Detection of Complications During Immunotherapy for Haematological Malignancy

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

BaseCAR-01

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

EMBRACE

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

PACER

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

MR-ICANS

Rhu-pGSN for Severe Covid-19 Pneumonia

Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

ULTRA-COVID

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

Keratinocyte Growth Factor and Cytokines in Burns.